Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InnaVirVax Strengthens Patent Protection of VAC-3S Immunotherapy

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
The Company reaches a new stage of development with the filing of a new European patent application for VAC-3S aimed at protecting the immune system of patients infected with HIV-1.

InnaVirVax has announced that a new European patent application has been filed on VAC-3S, a (first-in-class) immunotherapy for the treatment of HIV infections.

This patent application claims the use of new immunogenic compositions that are optimized to induce a strong immune response in humans. It also relates to use of such immune compositions with enhanced properties compared to references.

This industrial property consolidation is based on the research undertaken by the Company since its inception, more than 3 years ago. It deals with an essential stake showing InnaVirVax’s ability to create value through innovation and patents.

Joël Crouzet, CEO of InnaVirVax declared: “For more than 3 years, InnaVirVax has had a proactive policy of construction and protection of its intellectual property by intensifying its international patents coverage. After the two patent applications filed last year on our DIAG-3S prognostic test and on an innovating vaccine, this new patent application protects our therapeutic vaccine currently under development. This corresponds to our will to build a strong and long-lasting scientific and medical project portfolio, the key of our future business successes”.

InnaVirVax is developing VAC-3S from a patent family covering Europe, the United States, Canada and China whose property belongs to Inserm and the AP-HP.

InnaVirVax has been granted an exclusive worldwide license since May 2009.

This immunotherapy is currently under phase I/IIa clinical development. The clinical trial is being conducted since February 2012 in two major clinical reference centers in Paris: the Pitié Salpêtrière and Cochin Hospitals. It involves 24 patients infected with HIV-1 whose viral load is controlled under antiretroviral therapy.

The primary endpoint is the safety of this immunotherapy. The immunogenicity of the candidate drug is also being studied, as are its effects on markers of HIV infection (notably the CD4 count, viral load and markers of cellular activation).

Patients are being immunized and then followed for one year. This clinical trial has been awarded a grant of €600,000 from OSEO, the French government-backed agency that supports innovation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine
Interim results of the phase I/IIa clinical study revealed a good safety and tolerability profile for the VAC-3S immunotherapeutic vaccine, which was the primary endpoint of the study performed in two AP-HP reference clinical centers in Paris, France, at Pitié Salpêtrière and Cochin Hospitals.
Monday, December 03, 2012
InnaVirVax Announces the Launch of the First Clinical Trial on VAC-3S
This trial is supported by a grant from the “OSEO” French Innovation Agency.
Tuesday, March 06, 2012
Scientific News
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
New Therapy Treats Autoimmune Disease Without Harming Normal Immunity
Preclinical study from Penn shows that engineered T cells can selectively target the antibody-producing cells that cause autoimmune disease.
Harnessing An Innate Repair Mechanism Enhances The Success Of Retinal Transplantation
Cross-species research in flies and mice could help solve a major roadblock to successful stem cell replacement therapies in degenerative diseases of the retina, including age-related macular degeneration.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!